Acorda Therapeutics, Inc. (ACOR)

Market Cap	19.48M
Revenue (ttm)	116.91M
Net Income (ttm)	-20.92M
Shares Out	1.30M
EPS (ttm)	-5.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,342
Open	15.03
Previous Close	14.50
Day's Range	14.05 - 15.03
52-Week Range	5.60 - 24.80
Beta	1.43
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2023

About ACOR

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 10, 2006
• Employees: 111
• Stock Exchange: NASDAQ
• Ticker Symbol: ACOR

Financial Performance

In 2022, ACOR's revenue was $118.57 million, a decrease of -8.14% compared to the previous year's $129.07 million. Losses were -$65.92 million, -36.59% less than in 2021.